# Alzheimer's disease drug development pipeline: 2024

*PRI Rank #8 · Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/alzheimer-s-disease-research-and-treatments/2026/rank-8*

| Field | Value |
| --- | --- |
| Rank | #8 |
| 18m citations | 196 |
| Journal | Alzheimer s & Dementia Translational Research & Clinical Interventions |
| Year | 2024 |
| DOI | 10.1002/trc2.12465 |
| Corresponding authors | Jeffrey L. Cummings |
| Institution | University of Nevada, Las Vegas, United States |

**Ranking page:** [Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers, Class of 2026](https://pri.pepkio.com/top-papers/alzheimer-s-disease-research-and-treatments/2026)

**Paper link:** [10.1002/trc2.12465](https://doi.org/10.1002/trc2.12465)

## Topics

Alzheimer's disease drug development · Common Alzheimer's Disease Research Ontology · disease-modifying biological agents · disease-modifying small molecule drugs · cognitive enhancing agents · neuropsychiatric symptoms treatment · Anti-amyloid therapy · neurotransmitter receptor-targeting therapies · synaptic plasticity-targeting therapies · inflammation-targeting therapies · new chemical entities · repurposed agents · Phase 1 clinical trials · Phase 2 clinical trials · Phase 3 clinical trial · ClinicalTrials.gov · drug repurposing · AD pipeline contraction 2023-2024 · FDA drug development timeline

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/alzheimer-s-disease-research-and-treatments/2026. Accessed 2026-07-24.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```